Similar articles for PMID: 25511243

Year	Number of Results
1906	1
1908	1
1909	1
1917	1
1937	2
1938	1
1953	1
2004	1
2005	3
2006	5
2007	8
2008	2
2009	3
2010	5
2011	13
2012	21
2013	10
2014	17
2015	13
2016	18
2017	11
2018	8
2019	6
2020	6
2021	1
2022	3
2024	0

1

Why the United States preterm birth rate is declining.

Schoen CN, Tabbah S, Iams JD, Caughey AB, Berghella V. Schoen CN, et al. Am J Obstet Gynecol. 2015 Aug;213(2):175-80. doi: 10.1016/j.ajog.2014.12.011. Epub 2014 Dec 12. Am J Obstet Gynecol. 2015. PMID: 25511243

2

Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety.

O'Brien JM, Lewis DF. O'Brien JM, et al. Am J Obstet Gynecol. 2016 Jan;214(1):45-56. doi: 10.1016/j.ajog.2015.10.934. Epub 2015 Nov 10. Am J Obstet Gynecol. 2016. PMID: 26558340 Review.

3

Treatment options and recommendations to reduce preterm births in women with short cervix.

Slager J, Lynne S. Slager J, et al. J Midwifery Womens Health. 2012 Jul;57 Suppl 1:S12-8. doi: 10.1111/j.1542-2011.2012.00210.x. J Midwifery Womens Health. 2012. PMID: 22776244

4

What agent should be used to prevent recurrent preterm birth: 17-P or natural progesterone?

Hall NR. Hall NR. Obstet Gynecol Clin North Am. 2011 Jun;38(2):235-46, ix-x. doi: 10.1016/j.ogc.2011.02.014. Obstet Gynecol Clin North Am. 2011. PMID: 21575799 Review.

5

Effectiveness of 17-α-hydroxyprogesterone caproate on preterm birth prevention in women with history-indicated cerclage.

Mackeen AD, Rafael TJ, Zavodnick J, Berghella V. Mackeen AD, et al. Am J Perinatol. 2013 Oct;30(9):755-8. doi: 10.1055/s-0032-1332799. Epub 2013 Jan 22. Am J Perinatol. 2013. PMID: 23341330

6

Cerclage, progesterone and α-hydroxyprogeterone caproate treatment in women at risk for preterm delivery.

Haram K, Mortensen JH, Morrison JC. Haram K, et al. J Matern Fetal Neonatal Med. 2014 Nov;27(16):1710-5. doi: 10.3109/14767058.2013.876003. Epub 2014 Mar 31. J Matern Fetal Neonatal Med. 2014. PMID: 24678618 Review.

7

Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States.

Petrini JR, Callaghan WM, Klebanoff M, Green NS, Lackritz EM, Howse JL, Schwarz RH, Damus K. Petrini JR, et al. Obstet Gynecol. 2005 Feb;105(2):267-72. doi: 10.1097/01.AOG.0000150560.24297.4f. Obstet Gynecol. 2005. PMID: 15684150 Clinical Trial.

8

Vaginal progesterone, cerclage or cervical pessary for preventing preterm birth in asymptomatic singleton pregnant women with a history of preterm birth and a sonographic short cervix.

Alfirevic Z, Owen J, Carreras Moratonas E, Sharp AN, Szychowski JM, Goya M. Alfirevic Z, et al. Ultrasound Obstet Gynecol. 2013 Feb;41(2):146-51. doi: 10.1002/uog.12300. Epub 2013 Jan 17. Ultrasound Obstet Gynecol. 2013. PMID: 22991337 Free article. Clinical Trial.

9

17-alpha hydroxyprogesterone caproate for preterm birth prevention: Where have we been, how did we get here, and where are we going?

Manuck TA. Manuck TA. Semin Perinatol. 2017 Dec;41(8):461-467. doi: 10.1053/j.semperi.2017.08.004. Epub 2017 Sep 22. Semin Perinatol. 2017. PMID: 28947068 Review.

10

Assisted reproductive technology surveillance--United States, 2011.

Sunderam S, Kissin DM, Crawford SB, Folger SG, Jamieson DJ, Barfield WD; Centers for Disease Control and Prevention (CDC). Sunderam S, et al. MMWR Surveill Summ. 2014 Nov 21;63(10):1-28. MMWR Surveill Summ. 2014. PMID: 25412164 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

138 results

Results by year